Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 1,167,175 | 1,097,033 | 1,249,026 | 773,689 | 594,189 |
| Cost of Goods | 211,122 | 267,723 | 200,154 | 142,953 | 71,041 |
| Gross Profit | 956,053 | 829,310 | 1,048,872 | 630,736 | 523,148 |
| Operating Expenses | 687,539 | 698,315 | 681,044 | 647,888 | 505,112 |
| Operating Income | 268,636 | 131,718 | 367,982 | -16,199 | 18,077 |
| Interest Expense | 69,286 | 109,674 | 44,398 | 40,246 | 58,309 |
| Other Income | 22,303 | 99,865 | -84,615 | 21,087 | 37,864 |
| Pre-tax Income | 221,653 | 121,909 | 238,969 | -35,358 | -2,368 |
| Income Tax | 15,662 | -25,282 | -12,115 | 30,919 | 15,883 |
| Net Income Continuous | 205,991 | 147,191 | 251,084 | -66,277 | -18,251 |
| Net Income | $205,991 | $147,191 | $251,084 | $-66,277 | $-18,251 |
| EPS Basic Total Ops | 1.55 | 1.13 | 1.91 | -0.51 | -0.14 |
| EPS Basic Continuous Ops | 1.55 | 1.13 | 1.91 | -0.51 | -0.14 |
| EPS Diluted Total Ops | 1.51 | 1.14 | 1.84 | -0.51 | -0.14 |
| EPS Diluted Continuous Ops | 1.49 | 1.15 | 1.83 | -0.51 | -0.14 |
| EPS Diluted Before Non-Recurring Items | 1.51 | 0.82 | 1.84 | -0.52 | -0.44 |
| EBITDA(a) | $282,189 | $145,224 | $381,785 | $-2,255 | $32,482 |